Page 85 - 81_04

19. Arias, M. Avances en el diagnóstico de la infección
tuberculosa. Arch Bronconeumol 2011; 47: 521-30.
20. a) Pai M, Zwerling A, Menzies D. Systematic review:
T cell-based assays for the diagnosis of latent
tuberculosis infection-an update. Ann Intern Med
2008; 149: 177-84. b) Dorman SE. New Diagnostic
Tests for Tuberculosis: Bench, Bedside, and Beyond.
Clin Infect Dis 2010; 50: S173-S177.
21. a) Kaufmann SHD, Lange Ch, Rao M, et al. Progress
in tuberculosis vaccine development and host-directed
therapies. A state of the art review. Lancet Resp Med
2014, 2: 301-20. b) Asensio JG, Aguiló N, Martín-
Montañés C. Nuevas vacunas contra la tuberculosis.
Investigación y Ciencia 2014; 38-46.
22. Mangtani P, Abubakar I, Ariti C, et al. Protection by
BCG vaccine against tuberculosis: A systematic
review of randomized controlled trials. Clin Infect Dis
2013; doi: 10.1093/cid/cit790.
23. Guilleron M, Quesniaux VFJ, Puzo G. Acylation State
of the Phosphatidylinositol Hexamannosides from
Mycobacterium bovis Bacillus Calmette Guérin and
Mycobacterium tuberculosis H37Rv and Its
Implication in Toll-like Receptor Response. J Biol
Chem 2003; 278: 29880-89.
24. Ottenhoff TH, Kaufmann SH. Vaccines against
tuberculosis: where are we and where do we need to
go?. PLoS Pathog 2012; 8: e1002607.
25. a) McShane H, Pathan AA, Sander CR, et al.
Recombinant modified vaccinia virus Ankara
expressing antigen 85A boosts BCG primed and
naturally acquired anti-microbial immunity in humans.
Nat Med 2004, 10: 1240–44. b) Tameris MD,
Hatherill M, Landry BS, et al. Safety and efficacy of
MVA85A, a new tuberculosis vaccine, in infants
previously vaccinated with BCG: a randomised,
placebo-controlled phase 2b trial. Lancet 2013; 381:
1021-28.
26. Arbues A, Aguilo JI, Gonzalo-Asensio J, et al.
Construction, characterization and preclinical
evaluation of MTBVAC, the first live-attenuated M.
tuberculosis-based vaccine to enter clinical trials.
Vaccine 2013; 31: 4867-73.
27. Vilaplana C, Montané E, Pinto S, et al. Double-blind,
randomized, placebo-controlled Phase I Clinical Trial
of the therapeutical antituberculous vaccine RUTI.
Vaccine 2010; 28: 1106-16.
28. Sponsor: Manresana de Micobacteriologia SL. Safety
and Immunogenicity of Nyaditum Resae® Probiotic to
Protect From Tuberculosis. ClinicalTrials.gov 2014;
Identifier: NCT02076139.
29. a) Green KD, Garneau-Tsodikova S. Resistance in
tuberculosis: what do we know and where can we go?
Front Microbiol 2013; 4: 208. b) Chung-Delgado K,
Guillén-Bravo S, Revilla-Montag A, Bernabe-Ortiz A.
Mortality among MDR-TB cases: comparison with
drug-susceptible tuberculosis and associated factors.
PLoS One 2015; 10: e0119332.
354
Carmen Avendaño
30. Dalton T, Cegielski P, Akksilp S, Asencios L, et al.
Prevalence of and risk factors for resistance to second-
line drugs in people with multidrug-resistant
tuberculosis in eight countries: A prospective cohort
study. Lancet 2012; 380: 1406–17.
31. Hwang TJ, Wares DF, Jafarov A, et al. Safety of
cycloserine and terizidone for the treatment of drug-
resistant tuberculosis: a meta-analysis. Internat J
Tuberculosis and Lung Disease 2013; 17: 1257-66.
32. Zumla A, Nahid P, Cole ST. Advances in the
development of new tuberculosis drugs and treatment
regimens. Nat Rev Drug Discov 2013; 12: 388-404.
33. Zumla A, Raviglione M, Hafner R, von Reyn CF.
Tuberculosis. N Engl J Med 2013; 368: 745-55.
34. Ver la web:
http://www.who.int/medicines/areas/quality assurance.
35. a) Mahajan R. Bedaquiline: First FDA-approved
tuberculosis drug in 40 years. Int J Appl Basic Med
Res 2013; 3: 1-2. b) Avorn J. Approval of a
tuberculosis drug based on a paradoxical surrogate
measure. JAMA 2013; 309: 1349-50.
36. Guillemont J1, Meyer C, Poncelet A, Bourdrez X,
Andries K. Diarylquinolines, synthesis pathways and
quantitative structure-activity relationship studies
leading to the discovery of TMC207. Future Med
Chem 2011; 3: 1345-60.
37. Segala E, Sougakof W, Nevejans-Chauffour A, Jarlier
V, Petrella S. New mutations in the mycobacterial
ATP synthase: new insights into the binding of the
diarylquinoline TMC207 to the ATP synthase C-ring
structure. Antimicrobial Agents Chemother 2012; 56:
2326-34.
38. Lessem EM, Bernardo J, C, DH. Informed use of
bedaquiline for tuberculosis. Lancet 2015; 385: 1724.
39. a) Xavier AS, Lakshmanan M. Delamanid: A new
armor in combating drug-resistant tuberculosis. J
Pharmacol Pharmacother 2014; 5: 222-4. b) Lewis
JM, Sloan DJ. The role of delamanid in the treatment
of drug-resistant tuberculosis. Ther Clin Risk Manag
2015; 11: 779-91.
40. Szumowski JD, Lynch JB. Profile of delamanid for the
treatment of multidrug-resistant tuberculosis. Drug
Des Devel Ther 2015; 9: 677-82.
41. a) Manjunatha U, Boshoff IMH, Barry CE. The
mechanism of action of PA-824. Commun Integr Biol
2009; 2: 215-18. b) Diacon AH, Dawson R, Hanekom
M, et al. Early Bactericidal Activity and
Pharmacokinetics of PA-824 in Smear-Positive
Tuberculosis Patients. Antimicrob Agents Chemother
2010; 54: 3402-07.
42. Upton AM, Cho S, Yang TJ, et al. In vitro and in vivo
activities of the Nitroimidazole TBA-354 against M.
tuberculosis. Antimicrob Agents Chemother 2015; 59:
136-44.
43. Ver:
http://www.newtbdrugs.org/project.php?id=48#sthash.
HvBZAUWr.dpuf.
@Real Academia Nacional de Farmacia. Spain